SpringWorks Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SWTX research report →
Range $47 – $78
Price Chart
About the company
SpringWorks Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative therapies for patient populations grappling with rare diseases and various forms of cancer, often those with significant unmet medical needs. The company's most advanced experimental treatment is nirogacestat, an orally administered small molecule that functions as a gamma secretase inhibitor.
- CEO
- Saqib Islam
- IPO
- 2019
- Employees
- 368
- HQ
- Stamford, CT, US
Get TickerSpark's AI analysis on SWTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.54B
- P/E
- -13.50
- Fwd P/E
- 27.27
- PEG
- -0.34
- P/S
- 18.48
- P/B
- 7.24
- EV/EBITDA
- -12.67
- Div Yield
- 0.00%
- Gross Margin
- 93.45%
- Op Margin
- -145.17%
- Net Margin
- -134.73%
- ROE
- -46.62%
- ROIC
- -56.88%
Latest fiscal year · YoY change
- Revenue
- $191.59M+3417.3%
- Gross Profit
- $179.04M+3463.0%
- Op Income
- $-278,131,000
- Net Income
- $-258,131,000+20.6%
- EPS
- $-3.48+32.4%
- OCF Growth
- +21.2%
- FCF Growth
- +21.8%
- 52W High
- $62.00
- 52W Low
- $28.21
- 50D MA
- $45.88
- 200D MA
- $41.19
- Beta
- 0.70
- RSI (14)
- 64
- Avg Volume
- 5.85M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SpringWorks posted continued strong OGSIVEO uptake in Q3 and said the launch is still early, while also preparing for a potential mirdametinib approval in early 2025.· November 12, 2024
- OGSIVEO net product revenue was $49.3 million in Q3, up 23% sequentially, and year-to-date revenue reached $110.5 million.
- Management said the desmoid tumor addressable population looks larger than initially estimated, citing about 10,000 unique patients identified through the new ICD-10 code versus an earlier estimate of 5,500 to 7,000.
- The blister-pack transition caused a July slowdown, but management said it is now largely complete and should improve adherence, refill visibility and economics.
- SpringWorks is on track for a February 28 PDUFA date for mirdametinib and is already building out commercial readiness in the U.S. and Europe.
- The company ended Q3 with $498 million in cash, cash equivalents and marketable securities and reiterated a path to profitability in the first half of 2026.
SpringWorks recorded $49.3 million of OGSIVEO net product revenue in Q3 2024, up 23% quarter-over-quarter. Year-to-date OGSIVEO net product revenue was $110.5 million. The company did not give a reported companywide EPS, gross margin, or total revenue figure in the transcript. It said operating expense increased versus Q3 2023 due to commercial activities for the OGSIVEO launch and the anticipated mirdametinib launch. Cash, cash equivalents and marketable securities were $498 million at quarter-end. Management said this balance sheet should fund operations through profitability, which it expects in the first half of 2026. No formal next-quarter or full-year financial guidance was given.
Saqib Islam emphasized that SpringWorks is making OGSIVEO the standard of care for desmoid tumors and believes the launch still has significant room to run. He pointed to a larger-than-expected patient population, strong physician enthusiasm, improved real-world data on longer treatment, and the new blister-pack format as reasons for confidence. On mirdametinib, he framed the drug as a potential first FDA-approved option for adults with NF1-PN and said launch preparations are on track ahead of the February 28 PDUFA. His tone was confident and expansive, with repeated comments that the company is only at the beginning of the opportunity.
Francis Perier focused on the quarter’s reported financials: $49.3 million of OGSIVEO net product revenue in Q3 and $110.5 million year-to-date. He said total operating expense increased versus Q3 2023 because of launch-related commercial spending for OGSIVEO and prep for mirdametinib. He highlighted a strong liquidity position with $498 million in cash, cash equivalents and marketable securities and said that should be enough to fund the business through profitability in the first half of 2026. He also said the company has a durable operating plan to support multiple global launches and continued pipeline investment.
Analysts focused heavily on the blister-pack transition, asking how much of the remaining 35% of patients still needed to move over and whether the July disruption could reverse in Q4; management said the transition is largely complete and expects better refill rates, adherence and pricing visibility going forward. Another key question was whether the desmoid market is bigger than previously thought, and management said the new ICD-10 code data imply the earlier 5,500 to 7,000 active-patient estimate was conservative. Analysts also asked about who is being treated on OGSIVEO and discontinuation/dose reduction patterns; management said patients are coming from across the treatment continuum and said fewer than 10% of starters had discontinued a year into launch, while dose-reduction visibility should improve as more patients move to the 100 mg and 150 mg blister packs. Finally, investors asked how 2025 could look versus the first launch year and how mirdametinib might compare; management said OGSIVEO should benefit from a larger market, stronger physician adoption and long-term data, while mirdametinib’s launch will build on the company’s commercial infrastructure and patient support capabilities.
The quarter showed sustained OGSIVEO momentum, with management saying August and September were the strongest months since launch and that demand recovered after the July blister-pack transition. They also described physician enthusiasm, broader community prescribing and a larger-than-expected patient pool as evidence that growth could continue beyond the first year. For mirdametinib, the company has priority review, commercial teams in place and believes the data support a differentiated profile in NF1-PN.
The July switch to blister packs temporarily slowed prescriptions, showing that operational transitions can affect near-term growth. The company is still lacking full visibility into dose reductions and refill behavior until the transition is fully complete, and management acknowledged the real-world treatment population and market size estimates are still evolving. On mirdametinib, approval is not yet secured, and the launch depends on the February 28 PDUFA and regulatory outcomes in both the U.S. and Europe.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.8%
- Shares Outstanding
- 75.35M
- Float Shares
- 72.94M
of shares held by institutions
352 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SWTX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Josh GottheimerHouse · NJ05 | Sell | Jul 2, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jul 1, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 29, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 19, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 18, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | May 9, 24 | Filing → |
| Chris JacobsHouse · NY27 | Buy | Dec 12, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Boxer Capital, LLC | 3.42M | 0 |
| Eagle Asset Management Inc | 273.48K | ▼ 54.37K |
| Nuveen Asset Management, LLC | 183.76K | ▼ 114.14K |
| Seven Eight Capital, LP | 56.78K | ▲ 7.55K |
| Orion Portfolio Solutions, LLC | 36.22K | ▲ 3.23K |
| Raymond James & Associates | 15.79K | ▲ 5.37K |
| Springhill Fund Asset Management (Hk) Co Ltd | 5.90K | ▲ 5.90K |
| Lindbrook Capital, LLC | 246 | ▲ 106 |
| First Horizon Advisors, Inc. | 58 | ▼ 1.17K |
| Fintrust Capital Advisors, LLC | 20 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 25 | Edris Badreddin | sell | 33,778 |
| Jul 1, 25 | Edris Badreddin | sell | 3,868 |
| Jul 1, 25 | Edris Badreddin | sell | 149,470 |
| Jul 1, 25 | Edris Badreddin | sell | 100,000 |
| Jul 1, 25 | Edris Badreddin | sell | 240,000 |
| Jul 1, 25 | Edris Badreddin | sell | 169,712 |
| Jul 1, 25 | Edris Badreddin | sell | 120,000 |
| Jul 1, 25 | Edris Badreddin | sell | 78,960 |
| Jul 1, 25 | LYNCH DANIEL | sell | 29,983 |
| Jul 1, 25 | LYNCH DANIEL | sell | 7,464 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SWTX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SWTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
globenewswire.com · Oct 21
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
globenewswire.com · Oct 21
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
globenewswire.com · Aug 18
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
globenewswire.com · Aug 18
Immunome: SpringWorks Buyout Informs The Potential Upside Here
seekingalpha.com · Aug 11
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
globenewswire.com · Jul 18
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
globenewswire.com · Jul 18
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
businesswire.com · Jul 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
